» Articles » PMID: 27417188

Effect of Administration Timing of Postchemotherapy Granulocyte Colony-stimulating Factor on Host-immune Cell Recovery and CD8 T-cell Response

Overview
Journal J Immunotoxicol
Publisher Informa Healthcare
Date 2016 Jul 16
PMID 27417188
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor, is a standard supportive therapy given during cancer treatment. It induces acceleration in neutrophil recovery through stimulation of mobilization of hematopoietic progenitors. Given that the latter is also induced by chemotherapy itself, the timing of administration of G-CSF postchemotherapy might impact the resultant overall effects. The present study aimed to determine the optimal timing of G-CSF postchemotherapy to exert its optimal effects on the immune cell recovery and its impact on antigen-specific CD8 T-cell response. B6 mice were treated once with cyclophosphamide (4 mg/mouse; CTX) and then daily with G-CSF (5 g/mouse) from Days 1-5, 2-5 or 5-9 post-CTX treatment. The total numbers of various immune cell types were analyzed on Days 7, 9 and 12 post-CTX treatment. To evaluate effects on CD8 T-cell response, a pmel-1 transgenic mouse model was used in combination with prime boost peptide vaccination therapy. The total number of white blood cells (WBC), neutrophils, monocytes, lymphocytes, granulocytes and dendritic cells (DC) were significantly increased after G-CSF treatment in particular when G-CSF was administered from Days 2-5 post-CTX treatment. Application of this timing of G-CSF and CTX treatment after adoptive transfer of T-cells followed by prime-boost vaccination with antigenic peptide did not block the expansion of the donor pmel-1 CD8 T-cells. In conclusion, adjusting the timing of treatment with G-CSF postchemotherapy can optimize its promoting effects on recovery of myeloid cells without altering the associated antigen-specific immunity.

Citing Articles

Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice.

Salem M, El-Bakry K, Moubark E, Sobh A, Khalil S Br J Biomed Sci. 2022; 79:10328.

PMID: 35996501 PMC: 9302549. DOI: 10.3389/bjbs.2022.10328.


Immunomodulatory Effects of Walp. Polysaccharides on an Immunosuppression Model Induced by Cyclophosphamide.

Fei W, Yue N, Li A, Yu S, Zhao D, Zhu Y J Immunol Res. 2022; 2022:1210890.

PMID: 35832646 PMC: 9273403. DOI: 10.1155/2022/1210890.


G-CSF induces CD15 CD14 cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment.

Maneta E, Fultang L, Taylor J, Pugh M, Jenkinson W, Anderson G Clin Transl Immunology. 2022; 11(5):e1395.

PMID: 35602884 PMC: 9114661. DOI: 10.1002/cti2.1395.


Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.

Donadio M, Carraro D, Torrezan G, de Mello C Ecancermedicalscience. 2022; 16:1344.

PMID: 35242225 PMC: 8831114. DOI: 10.3332/ecancer.2022.1344.


Neutrophils are mediators of metastatic prostate cancer progression in bone.

Costanzo-Garvey D, Keeley T, Case A, Watson G, Alsamraae M, Yu Y Cancer Immunol Immunother. 2020; 69(6):1113-1130.

PMID: 32114681 PMC: 7230043. DOI: 10.1007/s00262-020-02527-6.

References
1.
Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

2.
Salem M, Diaz-Montero C, Al-Khami A, El-Naggar S, Naga O, Montero A . Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009; 182(4):2030-40. PMC: 3066095. DOI: 10.4049/jimmunol.0801829. View

3.
Morikawa K, Morikawa S, Nakamura M, Miyawaki T . Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Br J Haematol. 2002; 118(1):296-304. DOI: 10.1046/j.1365-2141.2002.03574.x. View

4.
Salem M, Kadima A, El-Naggar S, Rubinstein M, Chen Y, Gillanders W . Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007; 30(1):40-53. DOI: 10.1097/01.cji.0000211311.28739.e3. View

5.
Yu J, Wheeler C, Zeltzer P, Ying H, Finger D, Lee P . Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001; 61(3):842-7. View